TACC3 and breast carcinoma: Of note, we further validated the broad applicability of the FGFR/HDAC inhibitor combination in other FGFR-fusion positive cancers by confirming the synergistic effects in urothelial bladder cancer cells and breast cancer cells containing the FGFR3-TACC3 fusion.